nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2023-11-01. See notice: 10.1155/2023/9850875.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-8143C2EF·Framework v5.0·Pipeline v0.4·Evaluated 01 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Pulmonary and Respiratory Medicine·Basis: Full text·Type: Diagnostic accuracy study

Tumor-Specificity Growth Factor Combined with Tumor Markers in Nuclear Medicine Imaging to Identify Prostate Cancer Osteonosus.

Zhang et al.Zhang, Chen·2021·Journal of healthcare engineering·10.1155/2021/7380120 ↗

In brief

A retrospective diagnostic accuracy study for prostate cancer bone disease whose circular reference standard and arithmetic errors invalidate its core performance claims.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

OBJECTIVE: This study has explored the application value of malignant tumor SPE growth factor (TSGF) combined with tumor markers (TM) (TSGF + TM) in nuclear medicine imaging to identify prostate cancer osteonosus (PCO).

METHODS: A retrospective analysis for 70 patients with prostate cancer and bone disease admitted to our hospital was performed, 30 healthy persons in the same period were selected as the control group, and the advantages and disadvantages of various examinations were analyzed. All patients were diagnosed with PET whole body bone imaging. Suspicious lesions could be examined by MRI or CT. According to the results of imaging examination, patients were divided into 40 cases of malignant prostate cancer and 30 cases of benign prostate cancer. All the patients underwent 18F-FDG-PET imaging, alpha-fetoprotein (AFP), and TSGF + TM determination. The case diagnosis results were compared and analyzed, and the sensitivity (SEN), specificity (SPE), and accuracy (ACC) of various detection methods were calculated. The SEN, SPE, and ACC of positron emission tomography (PET) were 90.9%, 57.8%, and 81.2%, respectively; those of TM were 79.2%, 94.6%, and 69.8%, respectively; and those of TSGF + TM were 95.9%, 100%, and 97.3%, respectively. The accuracy of combined diagnosis of tumors can reach 100%. The AFP and TSGF levels of serum TM were compared and analyzed, and it was found that the benign lesion group and the malignant lesion group showed significant increases compared with the control group, and the difference between the malignant lesion group and the control group was obvious (P < 0.05). SGF combined with TM could obtain a more definite diagnosis in PCO.

CONCLUSION: TSGF + TM combined with 18F-FDG-PET imaging showed important clinical value to diagnose the PCO. The imaging accuracy of TSGF + TM combined with 18F-FDG-PET is 97.3%, and the specificity of tumor diagnosis is 100%. Therefore, the TSGF + TM applied in medical imaging and identification of PCO was worthy of clinical promotion.

Strengths · Limitations

Strengths

#contribution

Clinically relevant diagnostic question addressed

The study targets an important clinical problem — improving diagnostic accuracy for prostate cancer bone disease — combining imaging and biomarker approaches, which represents a meaningful diagnostic strategy framework.

↳ §1 Introduction

#methodological rigour

Structured multi-method diagnostic comparison

The paper compares PET alone, TM alone, and combined TSGF+TM approaches with explicit diagnostic accuracy formulas, providing a framework for evaluating complementary diagnostic modalities.

↳ §2.5, §3.5–3.6, Figure 8

#application pathway

Real-world traction for combined diagnostics

The study addresses a genuine unmet need in oncology — clinicians managing advanced prostate cancer actively seek better tools for detecting bone metastasis — giving the research question inherent clinical relevance.

↳ §1 Introduction, §4 Conclusion

Limitations

#methodological rigour

Circular reference standard invalidates diagnostic accuracy

Patients are classified into malignant and benign groups based on PET whole body bone imaging (§2.1), and PET is then evaluated as one of the index tests for diagnostic accuracy. This circularity means PET's performance metrics are self-referential and invalid.

↳ §2.1 Research Objects

#methodological rigour

Arithmetic inconsistency in core diagnostic metrics

The reported TM accuracy of 69.8% is mathematically impossible given the stated sensitivity (79.2%), specificity (94.6%), and sample split (40 malignant, 30 benign), which should yield approximately 85.8%. The abstract claims 100% combined accuracy while the results report 97.3%.

↳ Abstract, Table 2, §3.6

#methodological rigour

Inappropriate biomarker selection for prostate cancer

AFP (alpha-fetoprotein) is described as a tumor marker for prostate cancer, but AFP is standard for hepatocellular carcinoma and germ cell tumors. PSA (prostate-specific antigen) is the established prostate cancer marker, raising fundamental questions about the biomarker panel's validity for this indication.

↳ §2.1, §3.4

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

This paper attempts to evaluate whether combining tumor-specificity growth factor (TSGF) with tumor markers and 18F-FDG-PET imaging improves diagnostic accuracy for prostate cancer bone disease. The clinical question is relevant, and the basic diagnostic comparison framework is appropriate. However, the study is undermined by a circular reference standard in which PET imaging is used both to classify patients and as an index test being evaluated, invalidating the core diagnostic accuracy calculations. The reported TM accuracy of 69.8% is arithmetically inconsistent with the paper's own sensitivity, specificity, and sample size data, indicating errors in the analytical pipeline. The use of AFP rather than PSA as the prostate cancer tumor marker, inconsistent terminology throughout (TSGF vs. TSGH), and a conclusion recommending 'clinical promotion' based on 70 patients from a single centre collectively represent substantial methodological and reporting problems that prevent the findings from supporting clinical decisions.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
1.7±0.2

Contribution
1.9

The paper addresses a clinically relevant question — combined biomarker and imaging diagnosis of prostate cancer bone disease — but does not clearly establish incremental advance over existing approaches. The recommendation for 'clinical promotion' based on N=70 from a single centre substantially exceeds the evidential base.

§1 Introduction, §4 Conclusion

worthy of clinical promotion

Methodological Rigour
1.5

The diagnostic accuracy framework is fundamentally compromised by a circular reference standard: patients are classified using PET imaging (§2.1), which is then evaluated as an index test. The TM accuracy figure (69.8%) is arithmetically inconsistent with the stated sensitivity (79.2%), specificity (94.6%), and sample split (40/30). AFP is used as a prostate cancer tumor marker despite being a hepatocellular/germ cell marker rather than PSA. Reliability concerns cap the editorial Methodological Rigour score at 2.0, though the merit-based score of 1.5 is already below this threshold.

§2.1, Abstract, Table 2, §3.5–3.6

patients were divided into 40 cases of malignant prostate cancer and 30 cases of benign prostate cancer

Reporting
2.0

The paper follows a conventional structure but is undermined by inconsistent terminology (TSGF vs. TSGH throughout), contradictory performance figures between abstract and results (100% vs. 97.3% accuracy), and inappropriately confident concluding language given the study's limitations.

Title, Abstract, Introduction, §3.6, §4 Conclusion

TSGH is a special substance produced by malignant tumor cells

Positioning
1.7

The introduction provides general prostate cancer background but does not engage substantively with the diagnostic accuracy literature for TSGF or competing biomarker combinations. The limitations section (§4) identifies only PET spatial resolution issues and does not address the circular gold standard, small sample, or single-centre design.

§1 Introduction, §4 Conclusion

Reliability

Concerns4 of 4 checks


Internal CoherenceConcern

Multiple specific numerical and terminological inconsistencies undermine the reported diagnostic performance metrics. The TM accuracy figure (69.8%) is arithmetically inconsistent with the stated sensitivity, specificity, and sample split. The abstract claims 100% combined accuracy while the results report 97.3%. TSGF and TSGH are used interchangeably throughout the manuscript.

Research ConductNoted

Ethics approval and informed consent are declared but the institutional name is redacted as 'XXX Orthopedic Hospital,' making the ethics declaration unverifiable. No conflict of interest statement, protocol registration, or adherence to diagnostic accuracy reporting standards (e.g., STARD) is reported.

Flags: 2 declared / 5 total

Reference IntegrityClean

All 23 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2023-11-01. See notice: 10.1155/2023/9850875.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Prostate cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesMedium
CitationsFWCI 0.6
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The diagnostic performance was demonstrated once in a single hospital's retrospective cohort of 100 subjects, which is proof of concept rather than independent validation.

From the paper
“TSGF + TM combined with 18F-FDG-PET imaging showed important clinical value for clinical diagnosis of PCO, which was worthy of clinical promotion.”

The paper names a real-world clinical use for its findings in diagnosing prostate cancer bone disease but does not specify which practitioners or services would adopt the combined method.

Pathway

Nuclear medicine physicians and oncology clinicians would combine TSGF and tumor marker testing with PET imaging to diagnose malignant bone lesions in prostate cancer patients.

Barrier

The evidence comes from a small single-center retrospective cohort without independent validation, so larger confirmatory studies are needed before clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Implications of Cranial Arterial Stenosis and Dolichoectasia for Cerebral Small-Vessel Disease Etiopathogenesis: Findings From a Prospective Mild Stroke Cohort

    Han, Clancy, Arteaga-Reyes, et al. · 2026 · Clinical medicine

    Primary claim

    These findings support a nonatheromatous, intrinsic microvascular pathology, particularly segmental arteriolar disorganization, as the principal mechanism of lacunar stroke and cSVD.

    Tentative
    Evidence Score
    3.4±0.1
    Reliability
    Caveats
  2. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

    Xu, Ren, Wang, et al. · 2025 · Basic medicine

    Primary claim

    We observed increased forced vital capacity at the highest dosage with a mean change of +98.4 ml (95% confidence interval 10.9 to 185.9) for patients in the 60 mg rentosertib QD group

    Tentative
    Evidence Score
    3.4±0.2
    Reliability
    Concerns
  3. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity

    Selvaraj, Livesey, Zhao, et al. · 2018 · Basic medicine

    Primary claim

    increased expression of GluA1 AMPA receptor (AMPAR) subunit occurs in MNs with C9ORF72 mutations that leads to increased Ca2+-permeable AMPAR expression and results in enhanced selective MN vulnerability to excitotoxicity.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats

How the rubric works →